Nexavar for melanoma looks like it's done according to a press release on the phase III clinical trial. Though the data is slated to be released at an "upcoming conference " researchers are now reporting a lack of efficacy for the drug combined with chemotherapy in advanced melanoma. Don't hold your breath for the journal publication though there are quite a few papers lamenting the dearth of "negative results" being published out there.

This is quoted from the ASCO email update circulated 3/31. We now have four drugs for renal cell cancer! The Wall Street Journal (3/31 Whalen) reports "The US Food and Drug Administration approved for sale a kidney-cancer drug that Novartis AG hopes to eventually expand to a variety of other cancers." Afinitor [everolimus] acts by targeting "a protein in the body that appears to underlie more than half a dozen types of cancer " the company stated.

Sorafenib is an oral multiple kinase inhibitor that targets both tumor-cell proliferation and angiogenesis. Approved in December 2005 for advanced renal cell carcinoma it is being further developed by the manufacturer for metastatic melanoma advanced primary liver cancer and NSCLC. Sorafenib has established potent anti-tumor activity in preclinical xenograft models of different tumor types by virtue of its anti-angiogenic anti-proliferative and proapoptotic effects.

Sorafenib shows encouraging results for advanced thyroid cancer

Sorafenib may help treatment of breast tumors

This is from an industry-sponsored website but there might be some value here have a look.

Bevacizumab plus sorafenib promising for ovarian cancer Phase I trial reported in JCO July 2008

Nexavar improves survival in liver cancer Get ready to pony up $5 400 per month!